Close

UPDATE: Oppenheimer Starts Aquestive Therapeutics (AQST) at Outperform

September 6, 2022 4:02 PM EDT
Get Alerts AQST Hot Sheet
Price: $0.92 -1.08%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 5 | New: 0
Join SI Premium – FREE
(Updated - September 6, 2022 4:04 PM EDT)

Oppenheimer analyst Francois Brisebois initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Outperform rating and a price target of $8.50.

The analyst comments "AQST is focused on the development and commercialization of products with its proven PharmFilm technology for anaphylaxis and epilepsy. As a testament to its platform's credibility, AQST currently has five FDA-approved products focused on CNS (largest product is Suboxone: blockbuster at peak). Following the recent CEO transition, we believe AQST is approaching an inflection point with the development of AQST-109 (sublingual film epinephrine for anaphylaxis) as its main value driver. Despite Libervant's (buccal film diazepam for refractory seizures) delays with the FDA (original PDUFA: 12/23/21 and Tentative Approval granted on 8/31/22), we believe AQST's current revenues (Sympazan + licensing business) alone are underappreciated at this stock price and justify our Outperform rating. We are initiating coverage with an $8.50 price target."

For an analyst ratings summary and ratings history on Aquestive Therapeutics click here. For more ratings news on Aquestive Therapeutics click here.

Shares of Aquestive Therapeutics closed at $1.31 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

PDUFA, FDA